Shawn Patrick Griffin

picture of Shawn Patrick Griffin

Health Sciences Assistant Clinical Professor, Department of Clinical Pharmacy Practice
School of Pharmacy & Pharmaceutical Sciences

Pharm.D., UNC Eshelman School of Pharmacy, 2014
B.S., Boston College, 2010, Biology

Phone: (949)824-8009

University of California, Irvine
110C Med Surge I
Mail Code: 3958
Irvine, CA 92697
Research Interests
Leukemia, stem cell transplant, cellular therapy, pharmacotherapy, dosing of medications in obesity, graft versus host disease, supportive care
Short Biography
Shawn Griffin is a Health Sciences Assistant Clinical Professor in the Department of Clinical Pharmacy Practice at the University of California, Irvine (UCI) School of Pharmacy & Pharmaceutical Sciences. He was hired as a founding faculty member within the new Doctor of Pharmacy Program and is currently developing both didactic and experiential courses for student pharmacists. Griffin also practices as a Board Certified Oncology Pharmacist within the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center where he has worked to create new pharmacist-provided clinical services. His research interests include investigating the role of pharmacists in clinical practice and optimizing the dosing of oncology-related medications in special populations.
Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin SP, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leukemia & Lymphoma. 2021;Online ahead of print. doi: 10.1080/10428194.2021.1907378.
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin SP, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. American Journal of Hematology. 2020;95(8):937-43. doi: 10.1002/ajh.25838.
Chen F, Wu X, Niculite C, Gilca M, Petrusca D, Rogozea A, Rice S, Guo B, Griffin SP, Calin GA, Boswell HS, Konig H. Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. Journal of Cellular and Molecular Medicine. 2020;24(13):7378-92. doi: 10.1111/jcmm.15339.
Agrawal A, Ranganath P, Ervin KD, Schmidt CA, Cox EA, Nelson RP, Schwartz JE, Abu Zaid M, Abonour R, Robertson MJ, Brinda BJ, Griffin SP, Thakrar TC, Farag SS. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome. Bone Marrow Transplantation. 2020;Online ahead of print. doi: 10.1038/s41409-020-0987-1.
Hickey EL, Clemons B, Griffin SP, Cox J, Sutphin S, Ramlal R, Benitez L. Multi-center Evaluation of Arsenic Trioxide Dosing in Obese Patients with Low-Intermediate Risk Acute Promyelocytic Leukemia. Leukemia & Lymphoma. 2019;60(14):3557-60. doi: 10.1080/10428194.2019.1639163.
Griffin SP, Wheeler SE, Wiggins LE, Murthy HS, Hsu JW, Richards AI. Pharmacokinetic and Clinical Outcomes When Ideal Body Weight is Used to Dose Busulfan in Obese Hematopoietic Stem Cell Transplant Recipients. Bone Marrow Transplantation. 2019;54(2):218-225. doi: 10.1038/s41409-018-0240-3.
Griffin SP, Nelson JE. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. Progress in Transplantation. 2016; 26(4):314-321. doi: 10.1177/1526924816667950.
Professional Societies
American Society for Transplantation and Cellular Therapy
Hematology/Oncology Pharmacy Association
Last updated